JUN 21, 2018 10:30 AM PDT

Setting Up Next-Generation Sequencing for the Needs of Routine Molecular Diagnostics With a Focus on the Suitability of the GeneReader NGS System for Lung Cancer Patients

Sponsored by: QIAGEN
Speaker
  • Head of the Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Head of the Human Biobank Unit, Pasteur Hospital
    Biography
      Paul Hofman obtained his MD degree in 1989 at the University Côte d'Azur (Nice, France) and his PhD in 1994 at the University of Montpellier I (Montpellier, France). Having completed research fellowships in the Department of Pathology at the Brigham and Women's Hospital (Harvard Medical School, Boston, USA) and at the Max Planck Institut (Tubingen, Germany), he became full Professor of Pathology and Head of a research team at the Inserm 1081/UMR CNRS 7284 (IRCAN; www.ircan.org), located at the Comprehensive Cancer Center Antoine Lacassagne (Nice) in 1995. His group's research focus is lung cancer pathophysiology and the discovery of predictive and prognostic biomarkers. Paul is also head of the Hospital-related Biobank (BB-0033-00025) and of the Laboratory of Clinical and Experimental Pathology at Nice Hospital as well as being Director of the OncoAge Consortium in France (www.oncoage.org). He has published more than 450 peer review publications.

    Abstract

    The introduction of targeted therapies into the clinical management of lung adenocarcinoma has had a massive impact on patient care. Multiple driver mutations are now druggable and treatments differ depending on the mutational pattern of each patient with advanced lung adenocarcinoma. Consequently, mutational analysis is critical for treatment decisions in clinical routine practice. While several techniques have been developed and introduced into clinical care over the past few years, next-generation sequencing (NGS) has evolved to become the new standard in molecular diagnostics for most institutions. Thus, the development of targeted sequencing panels, which only cover specific and relevant mutations, make NGS affordable and suitable for high-throughput processing. There is no consensus system for individual sample tracking and the storage of meta information which is therefore required to be set up in each diagnostic laboratory individually. Additionally, setting up a NGS workflow requires well-trained personal, complex workflows and the need for specialized bioinformatics to analyze and interpret the results. Two different sequencing techniques were established initially for NGS in clinics, the Ion Personal Genome Machine (PGM) and Illumina sequencing. While both systems are based on fundamentally different sequencing principles, their purpose for clinical mutation analysis is quite similar. However, both systems require each diagnostic laboratory to develop their own workflow, leading to a plethora of “homebrew” solutions as different devices for sample preparation can be integrated in the respective workflows

    QIAGEN developed a novel sequencing system, the GeneReader, specifically designed for the needs of routine molecular diagnostics. In contrast to the existing solutions, the GeneReader system provides a complete workflow from sample preparation to data analysis. This reduced hands-on time during sample preparation, increased sample traceability and reproducibility address many of the issues of “homebrew” NGS solutions. Bioinformatic analysis is well integrated into the workflow and automated to strongly improve the quality and efficacy. The GeneReader can easily be installed and integrated into a routine pathology laboratory. Only limited training of the technical personnel is necessary. The high traceability is a strong advantage for daily routine sequencing and maybe very helpful for easily getting an accreditation according to the ISO 15189 norm. 

    Here we will present the main characteristics of the GeneReader NGS system and the potential for using this system in daily practice. We demonstrate the suitability of the GeneReader NGS system in routine in a clinical and molecular pathology laboratory setting.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 18, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 18, 2021 8:00 AM PDT
    DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    JUN 21, 2018 10:30 AM PDT

    Setting Up Next-Generation Sequencing for the Needs of Routine Molecular Diagnostics With a Focus on the Suitability of the GeneReader NGS System for Lung Cancer Patients

    Sponsored by: QIAGEN

    Specialty

    Molecular Biology

    Molecular Diagnostics

    Biotechnology

    Cancer

    Laboratory Testing

    Research And Development

    T-Cells

    Gene Sequencing

    Dna

    Personalized Medicine

    Cancer Diagnostics

    Research

    University

    Tumor

    Dna Sequencing

    Geography

    North America50%

    Asia25%

    Europe25%

    Registration Source

    Website Visitors100%

    Job Title

    Medical Laboratory Technician50%

    Student17%

    Clinical Laboratory Scientist17%

    Biologist17%

    Organization

    Clinical Laboratory25%

    Academic Institution25%

    Government/public13%

    Hospital13%

    Manufacturer - Other13%

    Other13%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more